Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?

by Owen, Dwight H., Otterson, Gregory A.
Published in J Thorac Dis (2018)

DLL3: an emerging target in small cell lung cancer

by Owen, Dwight H., Giffin, Michael J., Bailis, Julie M., Smit, Marie-Anne Damiette, Carbone, David P., He, Kai
Published in J Hematol Oncol (2019)

Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers

by Jain, Natasha A, Zhao, Songzhu, Wei, Lai, Rogers, Kerry A, Otterson, Gregory A, Wang, Tzu-Fei, Owen, Dwight H
Published in Cancer Manag Res (2020)

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer

by Owen, Dwight H., Konda, Bhavana, Sipos, Jennifer, Liu, Tom, Webb, Amy, Ringel, Matthew D., Timmers, Cynthia D., Shah, Manisha H.
Published in J Natl Compr Canc Netw (2019)

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With None–Small-cell Lung Cancer

by Owen, Dwight H., Wei, Lai, Bertino, Erin M., Edd, Thomas, Villalona-Calero, Miguel A., He, Kai, Shields, Peter G., Carbone, David P., Otterson, Gregory A.
Published in Clin Lung Cancer (2018)

Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer

by Owen, Dwight H., Williams, Terence M., Bertino, Erin M., Mo, Xiaokui, Webb, Amy, Schweitzer, Catherine, Liu, Tom, Roychowdhury, Sameek, Timmers, Cynthia D., Otterson, Gregory A.
Published in Lung Cancer (2019)

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltrans...

by Owen, Dwight H., Alexander, Andrew J., Konda, Bhavana, Wei, Lai, Hemminger, Jessica A., Schmidt, Carl R., Abdel-Misih, Sherif R.Z., Dillhoff, Mary E., Sipos, Jennifer A., Kirschner, Lawrence S., Shah, Manisha H.
Published in Oncotarget (2017)

Deep and durable response to nivolumab and temozolomide in small cell lung cancer associated with an early decrease in myeloid-derived suppressor cells.

by Owen, Dwight H., Benner, Brooke, Pilcher, Carly, Good, Logan, Savardekar, Himanshu, Norman, Ruthann, Ghattas, Christian, Shah, Manisha, Konda, Bhavana, Verschraegen, Claire F., Wesolowski, Robert, Behbehani, Gregory K., Carson, William E., Otterson, Gregory A.
Published in Clin Lung Cancer (2020)

Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy

by Johns, Andrew C., Sorenson, Chad, Rogers, Alan, Agne, Julia L., D’Souza, Desmond M., Das, Jishu K., Issa, Majd, Perna, Gina, Williams, Terence M., Meara, Alexa, Kitchin, Trevor, Haglund, Karl E., Owen, Dwight H.
Published in Clin Lung Cancer (2020)

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

by Li, Mingjia, Spakowicz, Daniel, Burkart, Jarred, Patel, Sandip, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Carbone, David P., Verschraegen, Claire F., Presley, Carolyn J., Otterson, Gregory A., Kendra, Kari, Owen, Dwight H.
Published in J Cancer Res Clin Oncol (2019)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

by Bond, David A, Huang, Ying, Fisher, James L, Ruppert, Amy S, Owen, Dwight H, Bertino, Erin M, Rogers, Kerry A, Bhat, Seema A, Grever, Michael R, Jaglowski, Samantha M, Maddocks, Kami J, Byrd, John C, Woyach, Jennifer A
Published in Leukemia (2020)

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

by Li, Mingjia, Spakowicz, Daniel, Zhao, Songzhu, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Miah, Abdul, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Wei, Lai, Carbone, David P., Otterson, Gregory A., Presley, Carolyn J., Owen, Dwight H.
Published in Cancer Immunol Immunother (2020)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

by Abu-Sbeih, Hamzah, Ali, Faisal S., Naqash, Abdul Rafeh, Owen, Dwight H., Patel, Sandipkumar, Otterson, Gregory A., Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K., Wang, Yinghong
Published in J Clin Oncol (2019)

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

by Spakowicz, Daniel, Hoyd, Rebecca, Muniak, Mitchell, Husain, Marium, Bassett, James S., Wang, Lei, Tinoco, Gabriel, Patel, Sandip H., Burkart, Jarred, Miah, Abdul, Li, Mingjia, Johns, Andrew, Grogan, Madison, Carbone, David P., Verschraegen, Claire F., Kendra, Kari L., Otterson, Gregory A., Li, Lang, Presley, Carolyn J., Owen, Dwight H.
Published in BMC Cancer (2020)

Checkpoint Inhibitor Immunotherapy Toxicity and Overall Survival among Older Adults with Advanced Cancer

by Johns, Andrew C., Wei, Lai, Grogan, Madison, Hoyd, Rebecca, Bridges, John F.P., Patel, Sandipkumar H., Li, Mingjia, Husain, Marium, Kendra, Kari L., Otterson, Gregory A., Burkart, Jarred T., Rosko, Ashley E., Andersen, Barbara L., Carbone, David P., Owen, Dwight H., Spakowicz, Daniel J., Presley, Carolyn J.
Published in J Geriatr Oncol (2021)

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

by Abu-Sbeih, Hamzah, Faleck, David M., Ricciuti, Biagio, Mendelsohn, Robin B., Naqash, Abdul R., Cohen, Justine V., Sellers, Maclean C., Balaji, Aanika, Ben-Betzalel, Guy, Hajir, Ibraheim, Zhang, Jiajia, Awad, Mark M., Leonardi, Giulia C., Johnson, Douglas B., Pinato, David J., Owen, Dwight H., Weiss, Sarah A., Lamberti, Giuseppe, Lythgoe, Mark P., Manuzzi, Lisa, Arnold, Christina, Qiao, Wei, Naidoo, Jarushka, Markel, Gal, Powell, Nick, Yeung, Sai-Ching J., Sharon, Elad, Dougan, Michael, Wang, Yinghong
Published in J Clin Oncol (2020)